Pervasis Therapeutics, Inc. is developing biologically active therapeutics to address complex diseases and unmet medical needs. With this objective, the company has developed technologies to regulate vascular repair and restore natural blood flow to critical organs. Their flagship product, Vascugel®, currently undergoing two Phase II clinical trials, is a cell-based therapeutic matrix developed to reestablish healthy vasculature after vascular injury. Vascugel® has the capability to be delivered in both open surgical and minimally invasive procedures. To date, Vascugel® has met all safety endpoints in ongoing clinical trials. Additionally, Pervasis is exploring broader indications in non-vascular applications.

Pervasis Therapeutics, Inc.
One Kendall Square
Building 600, 1st Floor
Cambridge, MA 02139

617-621-3407
info@pervasistx.com

News Highlights

January 15, 2008
Pervasis Therapeutics Closes Additional $9.75 Million in Financing [ PDF ]

September 17, 2007
Pervasis Therapeutics announces New Animal Study Results Supporting Vascugel® in Promoting Healing after Blood Vessel Injury [ PDF ]

August 13, 2007
Pervasis Therapeutics Successfully Completes Enrollment for Vascugel® Phase II Clinical Trials [ PDF ]

May 15, 2007
Pervasis Therapeutics, Inc. Named to Red Herring 100, Spring 2007 [ PDF ]

View more news